Podcasts about global neurology academy

  • 8PODCASTS
  • 192EPISODES
  • AVG DURATION
  • 5WEEKLY NEW EPISODES
  • Jun 2, 2025LATEST

POPULARITY

20172018201920202021202220232024


Best podcasts about global neurology academy

Latest podcast episodes about global neurology academy

NeuroFrontiers
Managing MS in Women: How to Guide Patients Through Pregnancy and Menopause

NeuroFrontiers

Play Episode Listen Later Jun 2, 2025


Guest: Riley Bove, MD, MMSc From pregnancy planning and postpartum relapse risk to the overlapping symptoms of menopause, women with multiple sclerosis (MS) face unique challenges throughout the reproductive lifespan. Here to share key takeaways from her session at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting that focused on how we can better care for these patients is Dr. Riley Bove, a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences.

Conference Coverage
Managing MS in Women: How to Guide Patients Through Pregnancy and Menopause

Conference Coverage

Play Episode Listen Later Jun 2, 2025


Guest: Riley Bove, MD, MMSc From pregnancy planning and postpartum relapse risk to the overlapping symptoms of menopause, women with multiple sclerosis (MS) face unique challenges throughout the reproductive lifespan. Here to share key takeaways from her session at the 2025 Consortium of Multiple Sclerosis Centers Annual Meeting that focused on how we can better care for these patients is Dr. Riley Bove, a practicing neurologist and clinician scientist in the UCSF Weill Institute for Neurosciences.

NeuroFrontiers
Tremor Relief with a Wearable Device: Exploring an Alternative to Medication and Surgery

NeuroFrontiers

Play Episode Listen Later May 14, 2025


Host: Jerome Lisk, MD, MBA, M.S., FAAN Guest: Emile Maamary Guest: Mark Elias For patients with who struggle with daily activities due to Parkinson's disease or essential tremor, treatment options are mostly limited to medication and invasive surgery. That's why Steadiwear co-founders Mark Elias and Emile Maamary developed an FDA-registered glove engineered to suppress hand tremors. Dr. Jerome Lisk sits down with Mr. Elias and Mr. Maamary to learn more about the device and its potential real-world impacts.

NeuroFrontiers
Supporting Adults With DMD: A Guide to Acute and Long-Term Planning

NeuroFrontiers

Play Episode Listen Later May 8, 2025


Guest: Rosaline Quinlivan As patients with Duchenne muscular dystrophy (DMD) transition from pediatric to adult care, they may encounter healthcare professionals—from primary care to emergency medicine—without prior experience managing their condition. Explore critical gaps in adult services for DMD and gain practical insights to help deliver timely, informed, and compassionate care with Dr. Rosaline Quinlivan, Professor of Neuromuscular Disease at University College London.

NeuroFrontiers
Transitioning to Adult Care in DMD: Strategies for Long-Term Support

NeuroFrontiers

Play Episode Listen Later May 8, 2025


Guest: Rosaline Quinlivan From sustained therapy and emergency planning to psychological support, coordinated care is essential as patients with Duchenne muscular dystrophy (DMD) transition into adulthood. Explore multidisciplinary approaches to optimize function, independence, and quality of life in adults with DMD with Dr. Rosaline Quinlivan, Professor of Neuromuscular Disease at University College London.

NeuroFrontiers
Improving Diagnostic Accuracy in MS: Criteria, Challenges, and Innovations

NeuroFrontiers

Play Episode Listen Later Apr 25, 2025


Guest: Andrew J. Solomon, MD Accurately diagnosing multiple sclerosis (MS) involves understanding the diagnostic criteria, recognizing red flags to avoid misdiagnosis, and keeping up with new tools. Dr. Andrew Solomon, Professor and Interim Chair of the Department of Neurological Sciences and Chief of the Multiple Sclerosis Division at the University of Vermont, walks through the most difficult aspects of diagnosing patients with MS and potential breakthroughs reshaping how we approach these challenges. Dr. Solomon also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Conference Coverage
Improving Diagnostic Accuracy in MS: Criteria, Challenges, and Innovations

Conference Coverage

Play Episode Listen Later Apr 25, 2025


Guest: Andrew J. Solomon, MD Accurately diagnosing multiple sclerosis (MS) involves understanding the diagnostic criteria, recognizing red flags to avoid misdiagnosis, and keeping up with new tools. Dr. Andrew Solomon, Professor and Interim Chair of the Department of Neurological Sciences and Chief of the Multiple Sclerosis Division at the University of Vermont, walks through the most difficult aspects of diagnosing patients with MS and potential breakthroughs reshaping how we approach these challenges. Dr. Solomon also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

NeuroFrontiers
Optimizing Neuromuscular Disease Care: How to Assess and Address Respiratory Risks

NeuroFrontiers

Play Episode Listen Later Apr 22, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Guest: Bethany Lussier, MD Respiratory decline in patients with neuromuscular diseases and mitochondrial myopathies can be challenging to identify, especially because its early signs may be subtle and vary from person to person. However, knowing how to evaluate a patient's respiratory function is key to improving outcomes and quality of life. Joining Dr. Charles Turck to discuss this importance and provide recommendations for optimizing respiratory care are Drs. Jason Ackrivo and Bethany Lussier. Dr. Ackrivo is an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania, and Dr. Lussier is an Associate Professor of Internal Medicine at UT Southwestern Medical Center and a member of its Division of Pulmonary and Critical Care Medicine.

Conference Coverage
Harnessing Neuroplasticity: Timing and Intensity in Post-Stroke Aphasia Intervention

Conference Coverage

Play Episode Listen Later Apr 16, 2025


Guest: Kelly Sloane, MD For patients who experience aphasia after a stroke, intervention and social support are crucial for recovery. Dr. Kelly Sloane, Assistant Professor of Neurology at the University of Pennsylvania, highlights how timely therapy and strong support systems can help rebuild both language and confidence in these patients. Dr. Sloane also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Conference Coverage
Inflammatory Gateways: Exploring the Role of the Choroid Plexus in Post-TBI Care

Conference Coverage

Play Episode Listen Later Apr 16, 2025


Guest: Prajwal Ciryam, MD, PhD Traumatic brain injuries (TBIs) trigger a rapid transcriptional response in the choroid plexus, dominated by chemokines that attract neutrophils. Join Dr. Prajwal Ciryam, Assistant Professor of Neurology at the University of Maryland School of Medicine, as he explains how this early signaling may represent a critical window for modulating inflammation in the injured brain. Dr. Ciryam also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

NeuroFrontiers
Inflammatory Gateways: Exploring the Role of the Choroid Plexus in Post-TBI Care

NeuroFrontiers

Play Episode Listen Later Apr 16, 2025


Guest: Prajwal Ciryam, MD, PhD Traumatic brain injuries (TBIs) trigger a rapid transcriptional response in the choroid plexus, dominated by chemokines that attract neutrophils. Join Dr. Prajwal Ciryam, Assistant Professor of Neurology at the University of Maryland School of Medicine, as he explains how this early signaling may represent a critical window for modulating inflammation in the injured brain. Dr. Ciryam also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

NeuroFrontiers
Harnessing Neuroplasticity: Timing and Intensity in Post-Stroke Aphasia Intervention

NeuroFrontiers

Play Episode Listen Later Apr 16, 2025


Guest: Kelly Sloane, MD For patients who experience aphasia after a stroke, intervention and social support are crucial for recovery. Dr. Kelly Sloane, Assistant Professor of Neurology at the University of Pennsylvania, highlights how timely therapy and strong support systems can help rebuild both language and confidence in these patients. Dr. Sloane also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Medical Industry Feature
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

Medical Industry Feature

Play Episode Listen Later Apr 5, 2025


Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.

Medical Industry Feature
From Diagnosis to Treatment: Challenges in Glioblastoma Care

Medical Industry Feature

Play Episode Listen Later Apr 5, 2025


Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

Medical Industry Feature
mIDH Gliomas Explained: Characteristics and Management Strategies

Medical Industry Feature

Play Episode Listen Later Apr 5, 2025


Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Conference Coverage
mIDH Gliomas Explained: Characteristics and Management Strategies

Conference Coverage

Play Episode Listen Later Apr 5, 2025


Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

NeuroFrontiers
From Diagnosis to Treatment: Challenges in Glioblastoma Care

NeuroFrontiers

Play Episode Listen Later Apr 5, 2025


Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

NeuroFrontiers
Climate Change in the Clinic: Examining Neurological Impacts

NeuroFrontiers

Play Episode Listen Later Apr 5, 2025


Guest: Beth Ann Malow, MD, MS The impacts of climate change present a growing threat to brain health. Rising heat, air pollution, and oxidative stress appear to worsen conditions like stroke, dementia, and multiple sclerosis. Join Dr. Beth Malow as she outlines the essential role clinicians play in prevention and education. Dr. Malow is a Professor of Neurology and Pediatrics and the Vice Chair for Academic Affairs in the Department of Neurology at Vanderbilt University Medical Center.

NeuroFrontiers
mIDH Gliomas Explained: Characteristics and Management Strategies

NeuroFrontiers

Play Episode Listen Later Apr 5, 2025


Guest: Jennie Taylor, MD Defined by the production of 2-hydroxyglutarate, mutant isocitrate dehydrogenase (mIDH) gliomas are diffuse, slow-growing tumors. Managing these tumors requires personalized strategies that consider resectability, histology, and long-term treatment impacts. Dr. Jennie Taylor, Assistant Professor of Neurology and Neurological Surgery at the University of California San Francisco, explains the complexities behind this type of tumor and implications for patient care. Dr. Taylor also spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

NeuroFrontiers
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

NeuroFrontiers

Play Episode Listen Later Apr 5, 2025


Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.

Conference Coverage
Climate Change in the Clinic: Examining Neurological Impacts

Conference Coverage

Play Episode Listen Later Apr 5, 2025


Guest: Beth Ann Malow, MD, MS The impacts of climate change present a growing threat to brain health. Rising heat, air pollution, and oxidative stress appear to worsen conditions like stroke, dementia, and multiple sclerosis. Join Dr. Beth Malow as she outlines the essential role clinicians play in prevention and education. Dr. Malow is a Professor of Neurology and Pediatrics and the Vice Chair for Academic Affairs in the Department of Neurology at Vanderbilt University Medical Center.

Conference Coverage
From Diagnosis to Treatment: Challenges in Glioblastoma Care

Conference Coverage

Play Episode Listen Later Apr 5, 2025


Guest: Lauren Schaff, MD Glioblastomas are fast, aggressive, and resistant to many standard therapies. Dr. Lauren Schaff, a neuro-oncologist at Memorial Sloan Kettering Cancer Center, explains how new molecular understandings and treatment avenues are paving the way for a more personalized, hopeful approach to care.

Conference Coverage
Vorasidenib and mIDH Gliomas: Reviewing the Efficacy Data

Conference Coverage

Play Episode Listen Later Apr 5, 2025


Guest: Jennie Taylor, MD The FDA approval of vorasidenib marks a new era for mutant isocitrate dehydrogenase (mIDH) gliomas. Approved in 2024 for grade 2 tumors after surgery, it doubled progression-free survival in the INDIGO trial. Dr. Jennie Taylor, Associate Professor of Neurology and Neurological Surgery at the University of California San Francisco, dives into the data and explains what questions remain about long-term use and broader applications.

NeuroFrontiers
Optimizing TK2d Care Through a Multidisciplinary Approach

NeuroFrontiers

Play Episode Listen Later Apr 4, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Kaitlin Batley, MD Guest: Esra Caylan, MD Thymidine kinase 2 deficiency (TK2d) presents with a variability of symptoms, including respiratory, neurological, and ocular ones, making it difficult to diagnose. Because of this, a multidisciplinary care team that's tailored to each patient's needs is key to effectively identifying and treating this disease. Hear about the role of a multidisciplinary team and strategies for personalizing treatment with Drs. Kaitlin Batley and Esra Caylan. Dr. Batley is the Director of Pediatric Neuromuscular Medicine at Children's Health and an Assistant Professor at UT Southwestern Medical Center. Dr. Caylan is a pediatric pulmonologist at Children's Health and an Assistant Professor in the Department of Pediatrics at UT Southwestern Medical Center.

Medical Industry Feature
Decoding CIDP: Pathogenesis, Diagnosis, and Clinical Clues

Medical Industry Feature

Play Episode Listen Later Apr 3, 2025


Guest: Hans Katzberg, MD Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a complex immune-mediated condition affecting the peripheral nervous system. Join Dr. Hans Katzberg, Professor of Medicine at the University of Toronto, as he explains the pathophysiology behind CIDP, risk factors in disease development, and diagnostic strategies.

Medical Industry Feature
Evolving Strategies in CIDP Care: Personalized Approaches and Emerging Treatments

Medical Industry Feature

Play Episode Listen Later Apr 1, 2025


Guest: Sami Khella, MD With personalized approaches, alternatives to steroids, and novel therapies like efgartigimod, the treatment landscape for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is continuing to evolve. Join Dr. Sami Khella as he shares expert insights on our available options. Dr. Khella is the Director of Clinical Electrophysiology and a Professor of Clinical Neurology at the University of Pennsylvania, and he spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Conference Coverage
Understanding CIDP: A Roadmap to Diagnosis

Conference Coverage

Play Episode Listen Later Apr 1, 2025


Guest: Sami Khella, MD Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) can present in multiple ways, making diagnosis complex. Dr. Sami Khella joins the program to outline how we can distinguish CIDP from similar neurological disorders and explain how response to therapy can guide diagnosis. Dr. Khella is the Director of Clinical Electrophysiology and a Professor of Clinical Neurology at the University of Pennsylvania, and he spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

Conference Coverage
Evolving Strategies in CIDP Care: Personalized Approaches and Emerging Treatments

Conference Coverage

Play Episode Listen Later Apr 1, 2025


Guest: Sami Khella, MD With personalized approaches, alternatives to steroids, and novel therapies like efgartigimod, the treatment landscape for chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is continuing to evolve. Join Dr. Sami Khella as he shares expert insights on our available options. Dr. Khella is the Director of Clinical Electrophysiology and a Professor of Clinical Neurology at the University of Pennsylvania, and he spoke about this topic at the 2025 American Academy of Neurology Annual Meeting.

ReachMD CME
Factoring Solutions to the Management of Stroke Care in the Settings of Secondary Prevention and AF

ReachMD CME

Play Episode Listen Later Mar 14, 2025


CME credits: 1.50 Valid until: 14-03-2026 Claim your CME credit at https://reachmd.com/programs/cme/factoring-solutions-to-the-management-of-stroke-care-in-the-settings-of-secondary-prevention-and-af/29099/ Despite significant efforts to prevent stroke in patients, there remains an unmet need among providers regarding the optimization and benefit-risk profile of anticoagulation therapies. Learn how these therapies may impact the prevention of ischemic stroke and secondary stroke in patients with atrial fibrillation. =

NeuroFrontiers
MS and Structural Disconnectivity: Pathophysiology and Emerging Technologies

NeuroFrontiers

Play Episode Listen Later Feb 27, 2025


Guest: Amy Kuceyeski, PhD In patients with multiple sclerosis, lesions in white matter can disrupt brain connectivity, leading to cognitive and motor impairments. Join Dr. Amy Kuceyeski as she discusses the pathophysiology behind structural disconnectivity and shares insights on new tools being developed to more accurately identify it in patients with multiple sclerosis. Dr. Kuceyeski is a Professor of Mathematics in Radiology and Neuroscience at Weill Cornell Medicine, and she spoke on this topic at the ACTRIMS Forum 2025.

NeuroFrontiers
Respiratory Challenges in Neuromuscular Disorders: A Look at Symptoms and Impacts

NeuroFrontiers

Play Episode Listen Later Feb 20, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Jason Ackrivo, MD, MSCE Respiratory complications are fairly common in patients with neuromuscular disorders, and given their vast impacts on a patient's prognosis and quality of life, it's critical to proactively detect and monitor any signs of respiratory decline. To learn more about the symptoms, impacts, and diagnosis of respiratory complications in patients with neuromuscular disorders, Dr. Charles Turck speaks with Dr. Jason Ackrivo. Not only is Dr. Ackrivo the Associate Director of the Fishman Program for Home Assisted Ventilation, but he's also an Assistant Professor of Medicine in Pulmonary, Allergy, and Critical Care at the Hospital of the University of Pennsylvania.

NeuroFrontiers
Navigating Neuromuscular Diseases: CHEST Guidelines for Respiratory Care

NeuroFrontiers

Play Episode Listen Later Feb 20, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Bimaje Akpa, MD Clinical practice guidelines from the American College of Chest Physicians provide recommendations for managing respiratory complications in patients with neuromuscular diseases, which can help inform our evaluation and treatment decisions. Joining Dr. Charles Turck to break down key insights from the CHEST guidelines and their impacts on clinical practice is Dr. Bimaje Akpa. Dr. Akpa is an Assistant Professor of Medicine in the Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine at the University of Minnesota.

NeuroFrontiers
Gaps in Schizophrenia Spectrum Disorders Care: A Look at Causes and Solutions

NeuroFrontiers

Play Episode Listen Later Feb 18, 2025


Guest: Natalie Bareis, PhD, LMSW Despite the availability of effective treatments for schizophrenia spectrum disorders, many patients are not receiving minimally adequate care based on a recent study. Tune in to hear Dr. Natalie Bareis discuss barriers to care, including the impact of substance use disorders and the limited availability of specialized programs, as well as how we can improve access and outcomes for patients with schizophrenia spectrum disorders. Dr. Bareis is an Assistant Professor of Clinical Behavioral Medicine in Psychiatry at Columbia University.

NeuroFrontiers
Understanding Schizophrenia: New Insights on Prevalence, Treatment, and Quality of Life

NeuroFrontiers

Play Episode Listen Later Feb 18, 2025


Guest: Natalie Bareis, PhD, LMSW A recent study on schizophrenia uncovered a significantly higher prevalence than previously estimated. The study also highlights ongoing struggles for patients, including low employment rates, poor general functioning, and limited access to adequate treatment. Join lead author Dr. Natalie Bareis as she discusses these findings and highlights the need for better policies and treatment accessibility. Dr. Bareis is an Assistant Professor of Clinical Behavioral Medicine in Psychiatry at Columbia University.

NeuroFrontiers
Respiratory Dysfunction in Neuromuscular Disorders: Evaluating Symptoms

NeuroFrontiers

Play Episode Listen Later Feb 12, 2025


Host: Charles Turck, PharmD, BCPS, BCCCP Guest: Hank Mayer, MD Patients with neuromuscular conditions often exhibit respiratory symptoms that impact their airway clearance and gas exchange, making it increasingly difficult for them to breathe. However, effective assessment techniques and early intervention can help mitigate the progression of this dysfunction, potentially keeping patients from needing extended recovery time or even inpatient care. Joining Dr. Charles Turck to discuss the importance of informed, proactive intervention for respiratory symptoms in patients with neuromuscular conditions is Dr. Hank Mayer. Dr. Mayer is the Medical Director of the Pulmonary Function Laboratory at the Children's Hospital of Philadelphia and a Professor of Clinical Pediatrics at the University of Pennsylvania's Perelman School of Medicine.

ReachMD CME
High-Efficacy DMTs: Transforming MS Care

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/high-efficacy-dmts-transforming-ms-care/32225/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
Long-Term Safety of DMTs: What We Know and What We Need to Know

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/long-term-safety-of-dmts-what-we-know-and-what-we-need-to-know/32226/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
PROs in MS: A New Era of Patient-Centric Care

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/pros-in-ms-a-new-era-of-patient-centric-care/32234/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
Balancing Act: Immune Reconstitution vs. Immune Suppression

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/balancing-act-immune-reconstitution-vs-immune-suppression/32227/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
From Pathology to Practice: The Role of Inflammation in MS Pathology

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/from-pathology-to-practice-the-role-of-inflammation-in-ms-pathology/32228/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
Fluid Biomarkers: Revolutionizing MS Diagnosis

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/fluid-biomarkers-revolutionizing-ms-diagnosis/32229/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
Imaging Biomarkers: MS Progression in Focus

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/imaging-biomarkers-ms-progression-in-focus/32230/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
Personalized Care for Diverse MS Populations: Special Populations Equal Special Care

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/personalized-care-for-diverse-ms-populations-special-populations-equal-special-care/32231/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
MS Cognitive Insights: Management, Diagnostic, and Treatment Strategies

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/ms-cognitive-insights-management-diagnostic-and-treatment-strategies/32232/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

ReachMD CME
Brain Health in MS: A Comprehensive Approach

ReachMD CME

Play Episode Listen Later Jan 24, 2025


CME credits: 1.00 Valid until: 24-01-2026 Claim your CME credit at https://reachmd.com/programs/cme/brain-health-in-ms-a-comprehensive-approach/32233/ This series of bite-sized episodes contains important information on the use of high-efficacy disease-modifying therapies (DMTs) in multiple sclerosis (MS). Drs. Ahmed Obeidat and Mark Freedman discuss the role of inflammation in MS pathology, treatment strategies for high-efficacy DMTs, impact on cognition, and use in special populations.

NeuroFrontiers
The Evolving gMG Treatment Landscape

NeuroFrontiers

Play Episode Listen Later Jan 20, 2025


Guest: Henry Kaminski, MD Generalized myasthenia gravis (gMG) is a complex autoimmune disease with a wide range of symptoms, from ocular issues to severe muscle weakness. As our understanding of the pathophysiology behind gMG evolves, so does our ability to improve patient management. Join Dr. Henry Kaminski as he examines emerging advancements in gMG treatment, including FcRN inhibitors and immune-targeting therapies. Dr. Kaminski is the Meta A. Neumann Professor of Neurology at the George Washington University School of Medicine and Health Sciences.

ReachMD CME
Spinal Muscular Atrophy: Optimizing the Management of Adults in the Era of Disease-Modifying Therapies

ReachMD CME

Play Episode Listen Later Jul 10, 2024


CME credits: 1.00 Valid until: 10-07-2025 Claim your CME credit at https://reachmd.com/programs/cme/spinal-muscular-atrophy-optimizing-the-management-of-adults-in-the-era-of-disease-modifying-therapies/26352/ Explore this on-demand webcast for an in-depth expert presentation and case discussion. This educational initiative is designed to help neurologists enhance their clinical approach by providing individualized, evidence-based care for adult SMA patients. Gain insights into the latest treatment options, safety and efficacy data, and effective patient communication strategies. Equip yourself with the knowledge to meet the unique clinical and psychosocial needs of adults with SMA and improve patient outcomes.=

ReachMD CME
Evolutions in Duchenne Muscular Dystrophy: Treatment Implications for the Present and Future

ReachMD CME

Play Episode Listen Later May 3, 2024


CME credits: 1.00 Valid until: 03-05-2025 Claim your CME credit at https://reachmd.com/programs/cme/evolutions-in-duchenne-muscular-dystrophy-treatment-implications-for-the-present-and-future/20369/ There are ongoing clinical trials and approvals for new genetic and non-genetic therapies for Duchenne muscular dystrophy. Determining the most suitable therapy for each patient is a developing process. This education covers dystrophin disruption and restoration, recent clinical trial outcomes from different treatment methods, and a case study exploring novel patient management strategies. =

ReachMD CME
On the Clinic Floor: Addressing the Most Critical Questions of Frontline Clinicians in Multiple Sclerosis Management

ReachMD CME

Play Episode Listen Later Apr 25, 2024


CME credits: 1.00 Valid until: 25-04-2025 Claim your CME credit at https://reachmd.com/programs/cme/on-the-clinic-floor-addressing-the-most-critical-questions-of-frontline-clinicians-in-multiple-sclerosis-management/16629/ The field of multiple sclerosis (MS) is evolving at a rapid pace from disease modifying therapies (DMTs) to diagnostic/monitoring tools to fundamental principles that shape how clinicians think about the disease. Though such advancements are welcome, they continue to raise new questions about how to optimize management for individual patients. In this program, real clinicians who treat MS pose their most pressing clinical questions to an expert panel. These specialists then provide their best answers through literature and their own clinical experience.=

ReachMD CME
New Frontiers in Optimizing Patient Outcomes in Multiple Sclerosis: Strategies for Early Intervention to Address Progression Independent of Relapse

ReachMD CME

Play Episode Listen Later Mar 20, 2024


CME credits: 1.00 Valid until: 20-03-2025 Claim your CME credit at https://reachmd.com/programs/cme/new-frontiers-in-optimizing-patient-outcomes-in-multiple-sclerosis-strategies-for-early-intervention-to-address-progression-independent-of-relapse/16478/ New strategies for early intervention in multiple sclerosis (MS) are focusing on progression independent of relapse. These strategies include incorporation of high-efficacy disease modifying therapies in the early stages of MS coupled with effective management of treatment-related adverse events. Join Drs. Stephen Kreiger, Tirisham Gyang, and Augusto Miravalle for a lively, case-based exchange that will provide key ideas to take back into the clinic.=